Skadden Leads Chinese Biotech Firm's $903M Hong Kong IPO
Chinese biotechnology firm BeiGene Ltd., represented by Skadden Arps Slate Meagher & Flom LLP, on Wednesday closed a $903 million initial public offering in Hong Kong, marking the first U.S.-listed company...To view the full article, register now.
Already a subscriber? Click here to view full article